Lung Program
At Premier, our physicians are internationally recognized experts in lung cancer. As part of the prestigious International Association for the Study of Lung Cancer (IASLC), our team has contributed to writing global guidelines for managing complex lung cancer cases. With over 20 publications on thoracic cancers—including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, and carcinoids—our expertise is widely respected.
Our physicians are frequently invited to speak at national and international conferences, including the renowned American Society of Clinical Oncology (ASCO) and the Florida Society of Clinical Oncology, sharing their knowledge and insights on lung cancer treatment.
The groundbreaking work by our team has been featured in the highly authoritative National Comprehensive Cancer Network (NCCN) Guidelines, and our physicians actively serve on the international Thoracic ReCOG group, collaborating with major cancer centers to develop treatments for recurrent cancers. We are particularly renowned for our expertise in Stereotactic Body Radiation Therapy (SBRT), also known as SABR, a cutting-edge technique in lung cancer care.
Our thoracic program brings together an elite team of specialists who participate in and lead tumor boards every Tuesday and Thursday at the BayCare system, working closely with top thoracic surgeons, medical oncologists, and pulmonologists. With deep connections to major cancer centers such as MD Anderson, Memorial Sloan Kettering, Loyola, and the UF Proton Therapy Center, we ensure that you have access to the latest trials and expert opinions whenever necessary. You can trust that, at Premier, we’re committed to providing you with the best possible care backed by global expertise.
Publications by Premier
- Solving access to lung cancer care across Europe
- Safe and effective systemic therapy for early-stage non-small-cell lung cancer
- How 3 Academic Centers Prescribe Stereotactic Body Radiation Therapy for Primary Lung Cancer
- An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone"
- An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer
- Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy
- Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC
- Proton therapy for non-small cell lung cancer: the road ahead
- Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms
- Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?
- Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer
- Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer
- Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
- 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial
- Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer
- Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma